Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7TV5I
|
|||
| Drug Name |
MK-4280
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Neoplasm [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphocyte activation gene 3 protein (LAG3) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02720068) Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction. J Immunol Methods. 2018 May;456:7-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.